Moleculin Price To Book Ratio from 2010 to 2024

MBRX Stock  USD 2.73  0.10  3.53%   
Moleculin Biotech Price To Book Ratio yearly trend continues to be fairly stable with very little volatility. Price To Book Ratio is likely to outpace its year average in 2024. Price To Book Ratio is a ratio used to compare a firm's market value to its book value, calculated by dividing the current closing price of the stock by the latest quarter's book value per share. View All Fundamentals
 
Price To Book Ratio  
First Reported
2010-12-31
Previous Quarter
0.97594615
Current Value
1.02
Quarterly Volatility
31.66200903
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Moleculin Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Moleculin Biotech's main balance sheet or income statement drivers, such as Interest Income of 965.1 K, Depreciation And Amortization of 120.7 K or Interest Expense of 2.3 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.02. Moleculin financial statements analysis is a perfect complement when working with Moleculin Biotech Valuation or Volatility modules.
  
Check out the analysis of Moleculin Biotech Correlation against competitors.
For more information on how to buy Moleculin Stock please use our How to Invest in Moleculin Biotech guide.

Latest Moleculin Biotech's Price To Book Ratio Growth Pattern

Below is the plot of the Price To Book Ratio of Moleculin Biotech over the last few years. It is a ratio used to compare a firm's market value to its book value, calculated by dividing the current closing price of the stock by the latest quarter's book value per share. Moleculin Biotech's Price To Book Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Moleculin Biotech's overall financial position and show how it may be relating to other accounts over time.
Price To Book Ratio10 Years Trend
Slightly volatile
   Price To Book Ratio   
       Timeline  

Moleculin Price To Book Ratio Regression Statistics

Arithmetic Mean(23.45)
Geometric Mean6.15
Coefficient Of Variation(135.00)
Mean Deviation29.97
Median0.63
Standard Deviation31.66
Sample Variance1,002
Range63.5619
R-Value0.85
Mean Square Error307.77
R-Squared0.71
Significance0.000072
Slope5.99
Total Sum of Squares14,035

Moleculin Price To Book Ratio History

2024 1.02
2023 0.98
2022 0.58
2021 0.63
2020 2.65
2019 2.39
2018 1.89

About Moleculin Biotech Financial Statements

Moleculin Biotech investors use historical fundamental indicators, such as Moleculin Biotech's Price To Book Ratio, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Moleculin Biotech. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Price To Book Ratio 0.98  1.02 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Moleculin Stock Analysis

When running Moleculin Biotech's price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.